Resources from the same session
LBA1 - CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
Presenter: Tina Cascone
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
LBA2 - ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)
Presenter: Ben Solomon
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA1 and LBA2
Presenter: Marina Garassino
Session: Presidential 1
Resources:
Slides
Webcast
Q&A
Presenter: Jean-Yves Blay
Session: Presidential 1
Resources:
Webcast
LBA3 - Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer
Presenter: Julien Hadoux
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: Jean-Yves Blay
Session: Presidential 1
Resources:
Webcast
LBA4 - Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
Presenter: Herbert Ho Fung Loong
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
LBA5 - Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study
Presenter: Nicolas Girard
Session: Presidential 1
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA4 and LBA5
Presenter: Benjamin Besse
Session: Presidential 1
Resources:
Slides
Webcast
Q&A
Presenter: Jean-Yves Blay
Session: Presidential 1
Resources:
Webcast